A(1-7) Reduces Pathologies Associated with SLE in MRL-lpr Mice
May 2018
in “
The Journal of Immunology
”
Studysummary In this study, daily treatment with angiotensin (1-7) significantly reduced disease severity in a mouse model of Systemic Lupus Erythematosus, suggesting potential for Mas agonists in future therapies.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study demonstrated that daily treatment with angiotensin (1-7) [A(1-7)] for 6 weeks significantly reduced various pathologies associated with Systemic Lupus Erythematosus (SLE) in MRL-lpr mice. The treatment led to lower levels of proteinuria, reduced glomerular pathologies, smaller lymph nodes, decreased levels of anti-dsDNA IgG, and less severe cutaneous pathologies, including reduced inflammation and hair loss, compared to saline-treated MRL-lpr mice. These findings suggested that A(1-7) could be a promising therapeutic target for SLE.
